Clicky

Medigene AG(MDG1)

Description: Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.


Keywords: Medicine Biotechnology Cancer Antibodies Immunotherapy Treatment Of Cancer Cancer Treatment Cancer Immunotherapy Immunotherapies Virotherapy Novel Cancer Dendritic Cell Medigene Cell Receptors

Home Page: www.medigene.com

Lochhamer Strasse 11
Munich, 82152
Germany
Phone: 49 89 2000 330


Officers

Name Title
Dr. Dolores J. Schendel Chief Scientific Officer, Member of Exec. Management Board and Head of R&D
Dr. Selwyn Ho MB BS, MBBS CEO & Member of Exec. Management Board
Dr. Ernst-Ludwig Winnacker Co-Founder & Chairman Scientific Advisory Board
Dr. Birger Kohlert Chief Financial Officer
Dr. Rene Goedkoop Acting Chief Medical Officer

Exchange: XETRA

Country: DE

Currency: Euro (€)

Forward PE: 0
Trailing PE: 5.641
Price-to-Book MRQ: 0.9095
Price-to-Sales TTM: 1.7882
IPO Date:
Fiscal Year End: December
Full Time Employees: 61
Back to stocks